

Amendment to the claims:

Please amend claim 22 and cancel claims 29 and 31 without prejudice.

Listing of Claims:

This listing of claims will replace all prior versions and listings of claims in the Application.

1 (Previously presented). A method for impairing movement of a cutaneous lymphocyte-associated antigen⁺ (CLA⁺) memory T-cell within or to the skin of a mammal, said method comprising administering to said mammal an effective amount of an antibody against cutaneous-T-cell-attracting chemokine (CTACK), whereby administration of said antibody impairs movement of said cutaneous lymphocyte-associated antigen⁺ memory T-cell within or to the skin of said mammal.

2 (Cancelled).

3 (Previously presented). The method of Claim 1, wherein said movement is within said skin.

4 (Previously presented). The method of Claim 1, wherein said antibody neutralizes cutaneous-T-cell-attracting chemokine.

Claims 5-21 (Cancelled)

22 (Currently amended). A method for treating a patient suffering from a skin disorder selected from the group consisting of allergic-contact dermatitis, ~~and psoriasis, wound healing and carcinoma~~ comprising administering an effective amount of an antibody against cutaneous-T-cell-attracting chemokine.

23 (Cancelled).

24 (Previously presented). The method of Claim 1, wherein said administering is local.

25 (Previously presented). The method of Claim 1, wherein said cutaneous lymphocyte-associated antigen⁺ memory T-cell moves into the dermis or epidermis of said skin.

26 (Cancelled).

27 (Previously presented). The method of Claim 22, wherein said skin disorder is allergic-contact dermatitis.

28 (Previously presented). The method of Claim 22, wherein said skin disorder is

psoriasis.

29 (Cancelled).

30 (Cancelled).

31 (Cancelled).

32 (Cancelled).

33 (Cancelled).

34 (Previously presented). The method of Claim 1, wherein said administering is systemic.

35 (Previously presented). The method of Claim 1, wherein said administering is topical.

36 (Previously presented). The method of Claim 1, wherein said administering is subcutaneous.

37 (Previously presented). The method of Claim 1, wherein said administering is intradermal.

38 (Previously presented). The method of Claim 1, wherein said administering is transdermal.